GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (OTCPK:SYGGF) » Definitions » Valuation Rank

SYGGF (Synairgen) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Synairgen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Synairgen Valuation Rank Related Terms

Thank you for viewing the detailed overview of Synairgen's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Synairgen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synairgen PLC (OTCPK:SYGGF) » Definitions » Valuation Rank
Comparable Companies
LSE:OBD LSE:HEMO LSE:IXI LSE:IMM AQSE:PBX LSE:FAB LSE:CIZ AQSE:INC LSE:POLB LSE:APTA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
SNG:UK OMY:Germany
Address
Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Website
https://www.synairgen.com
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.